Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score

Blood. 2018 Dec 20;132(25):2684-2686. doi: 10.1182/blood-2018-08-868406. Epub 2018 Nov 8.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Purpura, Thrombocytopenic, Idiopathic / blood
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / pathology
  • Registries*
  • Risk Assessment

Substances

  • Fibrinolytic Agents